Dare Bioscience Company Insiders
DARE Stock | USD 3.03 0.09 2.88% |
Dare Bioscience's insiders are aggressively buying. The analysis of insiders' sentiment of trading Dare Bioscience stock suggests that all insiders are extremely bullish at this time. Dare Bioscience employs about 21 people. The company is managed by 6 executives with a total tenure of roughly 23 years, averaging almost 3.0 years of service per executive, having 3.5 employees per reported executive.
Sabrina Johnson CEO President CEO, Secretary, Director |
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
2019-04-11 | Roger Hawley | Acquired 454545 @ 1.1 | View | ||
2018-06-11 | Roger Hawley | Acquired 140000 @ 1.45 | View | ||
2016-02-22 | David R Walt | Acquired 2291 @ 2.08 | View | ||
2016-02-18 | David R. Walt | Acquired 8960 @ 2.1 | View | ||
2016-02-16 | David R. Walt | Acquired 8811 @ 2 | View | ||
2016-02-11 | David R. Walt | Acquired 8850 @ 2.05 | View | ||
2016-02-09 | David R. Walt | Acquired 9000 @ 2.15 | View | ||
2016-02-05 | David R. Walt | Acquired 8563 @ 2.3 | View | ||
2016-02-03 | David R. Walt | Acquired 8413 @ 2.32 | View | ||
2016-02-01 | David R. Walt | Acquired 5700 @ 2.38 | View | ||
2016-01-28 | David R. Walt | Acquired 9000 @ 2.46 | View | ||
2016-01-26 | David R. Walt | Acquired 8800 @ 2.39 | View | ||
2016-01-25 | David R. Walt | Acquired 4500 @ 2.35 | View | ||
2016-01-22 | David R. Walt | Acquired 9000 @ 2.28 | View | ||
2016-01-20 | David R. Walt | Acquired 8900 @ 2.43 | View | ||
2016-01-15 | David R. Walt | Acquired 8572 @ 2.53 | View | ||
2016-01-13 | David R. Walt | Acquired 8684 @ 2.79 | View | ||
2016-01-11 | David R. Walt | Acquired 8855 @ 2.87 | View | ||
2016-01-07 | David R. Walt | Acquired 8800 @ 2.95 | View | ||
2016-01-05 | David R. Walt | Acquired 8801 @ 3.03 | View |
Monitoring Dare Bioscience's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dare Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. Dare Bioscience's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Dare Bioscience's future performance. Based on our forecasts, it is anticipated that Dare will maintain a workforce of about 40 employees by July 2025.Dare Bioscience Management Team Effectiveness
The company has return on total asset (ROA) of (0.8698) % which means that it has lost $0.8698 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.9469) %, meaning that it created substantial loss on money invested by shareholders. Dare Bioscience's management efficiency ratios could be used to measure how well Dare Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.0007, whereas Return On Tangible Assets are forecasted to decline to (0.19). At present, Dare Bioscience's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 21.1 M, whereas Net Tangible Assets are forecasted to decline to about 16.6 M.As of June 17, 2025, Common Stock Shares Outstanding is expected to decline to about 8.1 M. In addition to that, Net Loss is expected to decline to about (29.2 M)
Dare Bioscience Workforce Comparison
Dare Bioscience is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,293. Dare Bioscience claims roughly 21.0 in number of employees contributing just under 2% to equities under Health Care industry.
Dare Bioscience Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dare Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dare Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Dare Bioscience insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 0.4286 | 3 | 7 | 1,330,000 | 267,500 |
2020-03-01 | 1.5 | 3 | 2 | 416,000 | 225,000 |
2016-12-01 | 0.6667 | 8 | 12 | 68,426 | 438,819 |
2015-09-01 | 1.0 | 2 | 2 | 157,000 | 90,000 |
2015-06-01 | 2.1429 | 15 | 7 | 560,975 | 115,900 |
2014-09-01 | 2.0 | 2 | 1 | 36,100 | 35,765 |
2014-06-01 | 0.6961 | 71 | 102 | 21,401,996 | 153,525,351 |
Dare Bioscience Notable Stakeholders
A Dare Bioscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Dare Bioscience often face trade-offs trying to please all of them. Dare Bioscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Dare Bioscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Sabrina Johnson | President CEO, Secretary, Director | Profile | |
David Friend | Chief Officer | Profile | |
MarDee HaringLayton | Chief Officer | Profile | |
John Fair | Chief Business Officer | Profile | |
Lisa WaltersHoffert | Executive Officer | Profile | |
Mark Walters | Vice Operations | Profile |
About Dare Bioscience Management Performance
The success or failure of an entity such as Dare Bioscience often depends on how effective the management is. Dare Bioscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Dare management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Dare management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.18) | (0.19) | |
Return On Capital Employed | (47.65) | (45.27) | |
Return On Assets | (0.18) | (0.19) |
Please note, the presentation of Dare Bioscience's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dare Bioscience's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Dare Bioscience's management manipulating its earnings.
Dare Bioscience Workforce Analysis
Traditionally, organizations such as Dare Bioscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Dare Bioscience within its industry.Dare Bioscience Manpower Efficiency
Return on Dare Bioscience Manpower
Revenue Per Employee | 466 | |
Revenue Per Executive | 1.6K | |
Net Loss Per Employee | 193K | |
Net Loss Per Executive | 675.6K |
Complementary Tools for Dare Stock analysis
When running Dare Bioscience's price analysis, check to measure Dare Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dare Bioscience is operating at the current time. Most of Dare Bioscience's value examination focuses on studying past and present price action to predict the probability of Dare Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dare Bioscience's price. Additionally, you may evaluate how the addition of Dare Bioscience to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |